NEW YORK (GenomeWeb) – Foundation Medicine's stock rose today following an announcement that its FoundationOne CDx test was approved by the Centers for Medicare and Medicaid Services (CMS) as a new Advanced Diagnostic Laboratory Test (ADLT).
CMS classified FoundationOne CDx as an ADLT under the Protecting Access to Medicare Act (PAMA), a move that Foundation Medicine had said it was expecting.